Cancer treatment
Recent studies in the United States and United Kingdom have described breakthroughs in cancer vaccine development, focusing on novel approaches to stimulate the immune system against tumor cells. Researchers have explored the potential of combining different strategies, including OX40 costimulation, electroporation, and surrogate tumor antigen vaccination, to enhance antitumor immunity.
Cancer treatment
Researchers from Malaysia, South Korea, and Yugoslavia have made significant progress in cancer therapy, specifically in the treatment of non-small cell lung cancer (NSCLC). Three studies published in prominent medical journals have evaluated the efficacy and toxicity of various combinations of chemotherapy and radiotherapy regimens. The findings suggest that certain
Drugs
Pediatric cancer patients may benefit from new cancer therapies as research studies from the Netherlands, the United States, and Austria show promising results. Netherlands researchers found that pegfilgrastim, a long-lasting form of granulocyte colony-stimulating factor, can be safely administered to pediatric cancer patients to prevent neutropenia, a major side effect
Drugs
Researchers at the University of Seville in Spain have discovered that digitoxin, a cardiac glycoside, can inhibit cancer cell growth at concentrations commonly found in patients with cardiac disease. The study, published in the Journal of Natural Products, found that digitoxin was the most active compound in inhibiting growth in
Drugs
A novel study conducted by researchers at the Universite de Louvain in Brussels, Belgium, has found that the cosmetic treatment Botox may have a new use as an adjuvant to cancer therapy. Led by Bernard Gallez, PhD, professor of pharmacy, the study injected botulinum neurotoxin type A into two types
Drugs
Genentech's submission of a supplemental biologics license application (sBLA) to the U.S. Food and Drug Administration (FDA) for Herceptin in early-stage, HER2-positive breast cancer is based on a joint interim analysis of over 3000 patients from two phase III trials sponsored by the U.S. National Cancer
Drugs
Recent studies from the United States and the People's Republic of China have shed light on the complex molecular mechanisms underlying prostate cancer progression and metastasis. Three research studies have identified novel targets and therapeutic strategies that may offer new hopes for the treatment of this aggressive and
Drugs
Scientists have identified two CD8+ T-cell epitopes, VILTNPISM and FSNSTNDILI, from mouse VEGFR2 that can inhibit angiogenesis and tumor growth. These epitopes, discovered by researchers at the U.S. National Cancer Institute, were found to be effective in reducing angiogenesis and inhibiting tumor growth in mouse models. This discovery provides
Cancer treatment
Dendritic cells (DCs) have emerged as crucial players in cancer vaccine development due to their ability to initiate primary immune responses. Three studies from the United States, Belgium, and France have shed light on the maturation of human monocyte-derived dendritic cells, the role of prostaglandin E-2 (PGE2) in chemokine and
Cancer treatment
Researchers in the United States, China, and Japan have made significant breakthroughs in cancer vaccine research, with studies focusing on tumor-associated fibroblasts, exosomes, and heat shock proteins. These discoveries hold promise for the development of more effective immunotherapies against various types of cancer. By targeting specific antigens and modulating the
Drugs
A novel ATP-based Src family kinase inhibitor, AP23846, has been found to exhibit potent anti-cancer properties, particularly in tumor progression and metastasis. According to a study published in Molecular Cancer Therapeutics, AP23846 inhibited angiogenic protein in tumor cells, blocking the production of vascular endothelial growth factor (VEGF) and interleukin-8 (IL-8)
Drugs
M. D. Anderson Cancer Center, part of the University of Texas, has been awarded a three-year, $4.6 million Specialized Programs of Research Excellence (SPORE) grant from the U.S. National Cancer Institute for breast cancer research. This is the institution's 10th such grant since 1996, making it
